These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 34068036)
1. The Implications of Regulatory Framework for Topical Semisolid Drug Products: From Critical Quality and Performance Attributes towards Establishing Bioequivalence. Ilić T; Pantelić I; Savić S Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34068036 [TBL] [Abstract][Full Text] [Related]
2. Drilling down the bioequivalence assessment of topical antifungal products: Microstructure and release. Miranda M; Cardoso C; Pais AACC; Brown M; Vitorino C Eur J Pharm Biopharm; 2023 Apr; 185():94-106. PubMed ID: 36806630 [TBL] [Abstract][Full Text] [Related]
3. Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence. Mangas-Sanjuán V; Pleguezuelos-Villa M; Merino-Sanjuán M; Hernández MJ; Nácher A; García-Arieta A; Peris D; Hidalgo I; Soler L; Sallan M; Merino V Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31581492 [TBL] [Abstract][Full Text] [Related]
4. Diving into Batch-to-Batch Variability of Topical Products-a Regulatory Bottleneck. Miranda M; Cova T; Augusto C; Pais AACC; Cardoso C; Vitorino C Pharm Res; 2020 Oct; 37(11):218. PubMed ID: 33037479 [TBL] [Abstract][Full Text] [Related]
5. Topical bioequivalence: Experimental and regulatory considerations following formulation complexity. Miranda M; Veloso C; Brown M; C Pais AAC; Cardoso C; Vitorino C Int J Pharm; 2022 May; 620():121705. PubMed ID: 35358644 [TBL] [Abstract][Full Text] [Related]
6. Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms. Xu Z; Mangas-Sanjuán V; Merino-Sanjuán M; Merino V; García-Arieta A Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33260792 [TBL] [Abstract][Full Text] [Related]
7. Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation. Navarro-Pujol F; Bulut S; Hessman C; Karabelas K; Nieto C; Fernandez-Campos F Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959364 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic-driven framework for bioequivalence assessment of complex topical generic drug products. Lourenço D; Miranda M; Sousa JJ; Vitorino C Int J Pharm; 2024 Aug; 661():124398. PubMed ID: 38964491 [TBL] [Abstract][Full Text] [Related]
9. Critical quality attributes, in vitro release and correlated in vitro skin permeation-in vivo tape stripping collective data for demonstrating therapeutic (non)equivalence of topical semisolids: A case study of "ready-to-use" vehicles. Ilić T; Pantelić I; Lunter D; Đorđević S; Marković B; Ranković D; Daniels R; Savić S Int J Pharm; 2017 Aug; 528(1-2):253-267. PubMed ID: 28602800 [TBL] [Abstract][Full Text] [Related]
10. Quality and equivalence of topical products: A critical appraisal. Miranda M; Cardoso C; Vitorino C Eur J Pharm Sci; 2020 May; 148():105082. PubMed ID: 31626969 [TBL] [Abstract][Full Text] [Related]
11. Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union. García-Arieta A; Gordon J; Gwaza L; Merino V; Mangas-Sanjuan V Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839924 [TBL] [Abstract][Full Text] [Related]
12. In vitro studies into establishing therapeutic bioequivalence of complex topical products: Weight of evidence. Miranda M; Volmer Z; Cornick A; Goody A; Cardoso C; Pais AACC; Brown M; Vitorino C Int J Pharm; 2024 May; 656():124012. PubMed ID: 38537923 [TBL] [Abstract][Full Text] [Related]
13. Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study. Mañez-Asensi A; Hernández MJ; Mangas-Sanjuán V; Salvador A; Merino-Sanjuán M; Merino V Pharmaceutics; 2024 Jun; 16(6):. PubMed ID: 38931871 [TBL] [Abstract][Full Text] [Related]
14. Complying with the Guideline for Quality and Equivalence for Topical Semisolid Products: The Case of Clotrimazole Cream. Alves T; Arranca D; Martins A; Ribeiro H; Raposo S; Marto J Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33920061 [TBL] [Abstract][Full Text] [Related]
15. Topical Semisolid Products-Understanding the Impact of Metamorphosis on Skin Penetration and Physicochemical Properties. Jin X; Imran M; Mohammed Y Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432678 [TBL] [Abstract][Full Text] [Related]
16. Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system. Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C Eur J Pharm Sci; 2018 Sep; 122():264-272. PubMed ID: 29981406 [TBL] [Abstract][Full Text] [Related]
17. Update on the advances and challenges in bioequivalence testing methods for complex topical generic products. Alomari N; Alhussaini W Front Pharmacol; 2024; 15():1330712. PubMed ID: 38389924 [TBL] [Abstract][Full Text] [Related]
18. Relevance of equivalence assessment of topical products based on the dermatopharmacokinetics approach. Boix-Montanes A Eur J Pharm Sci; 2011 Feb; 42(3):173-9. PubMed ID: 21094254 [TBL] [Abstract][Full Text] [Related]
19. Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products. Renukuntla J; Palakurthi SS; Bolla PK; Clark BA; Boddu SHS; Manda P; Sockwell S; Charbe NB; Palakurthi S Int J Pharm; 2022 Nov; 627():122209. PubMed ID: 36162609 [TBL] [Abstract][Full Text] [Related]
20. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products. Chang RK; Raw A; Lionberger R; Yu L AAPS J; 2013 Jan; 15(1):41-52. PubMed ID: 23054971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]